biostudies-literatureBrenner TUniversitätsklinikum EssenInnovation Fund of the Federal Joint Committee714https://www.ebi.ac.uk/biostudies/studies/S-EPMC8522064biostudies-literatureUnknown22(1)<h4>Background</h4>Sepsis is triggered by an infection and represents one of the greatest challenges of modern intensive care medicine. With regard to a targeted antimicrobial treatment strategy, the earliest possible pathogen detection is of crucial importance. Until now, culture-based detection methods represent the diagnostic gold standard, although they are characterized by numerous limitations. Culture-independent molecular diagnostic procedures represent a promising alternative. In particular, the plasmatic detection of circulating, cell-free DNA by next-generation sequencing (NGS) has shown to be suitable for identifying disease-causing pathogens in patients with bloodstream infections.<h4>Methods</h4>The DigiSep-Trial is a randomized, controlled, interventional, open-label, multiceTrialsOptimization of sepsis therapy based on patient-specific digital precision diagnostics using next generation sequencing (DigiSep-Trial)-study protocol for a randomized, controlled, interventional, open-label, multicenter trial.PMC8522064NVF1_2020-060Grumaz SGreiner WBrenner TStevens PAxnick JPletz MWSkarabis ABruckner THaug PWitzke OBerger MMMarschall UAltin SRuprecht TMTIFOnet Critical Care Trials GroupLuntz SfalseOptimization of sepsis therapy based on patient-specific digital precision diagnostics using next generation sequencing (DigiSep-Trial)-study protocol for a randomized, controlled, interventional, open-label, multicenter trial.<h4>Background</h4>Sepsis is triggered by an infection and represents one of the greatest challenges of modern intensive care medicine. With regard to a targeted antimicrobial treatment strategy, the earliest possible pathogen detection is of crucial importance. Until now, culture-based detection methods represent the diagnostic gold standard, although they are characterized by numerous limitations. Culture-independent molecular diagnostic procedures represent a promising alternative. In particular, the plasmatic detection of circulating, cell-free DNA by next-generation sequencing (NGS) has shown to be suitable for identifying disease-causing pathogens in patients with bloodstream infections.<h4>Methods</h4>The DigiSep-Trial is a randomized, controlled, interventional, open-label, multice2021-01-01T00:00:00Z2021 Oct2026-05-27T23:25:43.95Z2024-12-04T13:03:41.864ZS-EPMC85220643466343910.1186/s13063-021-05667-x